Let’s see the other five Top 10 Best Selling drugs ranking from 6th to 10th.
Trastuzumab (trade name: Herceptin) is a humanized monoclonal antibody. It targets HER2, blocks the function of HER2 and prevents the growth and metastasis of cancer cells. Trastuzumab was approved by FDA in 1998 for the treatment of HER2 overexpression of metastatic breast cancer. In 2000, it was approved by the EU for the treatment of HER2-positive metastatic (advanced) breast cancer patients. In 2002, it was approved by CFDA and went public in China. By now, this drug has had biological similar drugs.
7. Prevnar 13
Prevnar 13 was approved by the FDA in the United States in 2010 for vaccination for children from 6 months to 5 years old. In 2016, Pfizer ranked first in the global vaccine market based on its Prevnar 13 and was ahead of other products. Prevnar 13 is a pneumococcal vaccine and has been stable in sales for many years.
Infliximab (trade name: Remicade), was approved by the US FDA in 1998 (followed by its sales right to Johnson & Johnson/Merck) for the treatment of patients with moderate to severe activity Crohn’s disease who has been treated with traditional method while failing to receive expected effects. Infliximab is the first drug approved by the US FDA and the European Medicines Review Administration (EMEA) for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, and Crohn’s disease. In 2007, Remicade was officially approved in China for the treatment of rheumatoid arthritis, ankylosing spondylitis and Crohn’s disease. Infliximab’s European patent expired in February 2015, and the FDA approved biosimilar drug Inflectra in May 2016. Infliximab is going to confront with great competitive pressures.
Etanercept (trade name: Enbrel) was approved by the US FDA in 1998 for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, forced spondylitis, and juvenile rheumatoid arthritis. In 2010, etanercept was approved in China for the treatment of moderate to severe rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Enbrel’s US patent protection should have been ended in 2012, but it was accidentally extended to 2028 due to the famous “submarine patent”.
10. Insulin Glargine
Sanofi’s insulin glargine (trade name: Lantus) is the world’s first long-acting insulin analogue, which was approved by the FDA in 2000 and listed in China in 2004, and has been dominating the global diabetes market for many years. In 2016, however, with Merck’s Lusduna approved by CHMP, Lilly’s Abasaglar approved by FDA, and the release of Lantus’ upgraded product Toujeo (already approved by the FDA) by itself, Lantus’ sales will show a declining trend.
The pharmaceutical industry is always changing. The newly listed drugs in 2017 may also go against our expectation. Let’s wait and see the actual statistics at the end of this year.
For the first five best selling drugs, please visit Prediction of the Top 10 Best Selling Drugs in 2017 (I).